Akin Gump Counsels CITIC in Buyout Bid for Chinese Biotech Firm

September 12, 2012

Reading Time : 1 min

Contact:

Jacinta O'Shea-Ramdeholl

Director of Communications

Sarah Richmond

Senior Communications Manager

Akin Gump is advising a unit of China’s CITIC Private Equity Funds Management Co. in its buyout bid, as part of a consortium, for Chinese biotech firm 3SBio Inc.  The deal would value the company at $331 million and take it private.

3SBio is based in Shenyang, China, and focuses on R&D, manufacturing and marketing biopharmaceutical products, primarily in China, related to nephrology, oncology and infection diseases, among others.

Share This Insight

Related Services, Sectors, and Regions

© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.